NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants..

宾夕法尼亚州纽顿，2025年6月4日（GLOBE NEWSWIRE）——Helius Medical Technologies, Inc.（纳斯达克股票代码：HSDT）（“Helius”或“公司”），一家专注于为平衡和步态缺陷提供新型治疗性神经调节方法的神经技术公司，今天宣布了其公开发行的定价，此次发行总计2,768,600股A类普通股（或普通股等价物），以及可购买多达2,768,600股普通股的认股权证，每股及附带认股权证的合计公开发售价格为3.27美元。

Each Warrant will expire two and one-half (2.5) years from the issuance, will be immediately exercisable upon issuance at an initial exercise price of $7.3575 per share, subject to adjustment on the First Reset Date and the Second Reset Date (as defined in the warrants) and subject to a floor price therein.

每份认股权证自发行之日起两年半（2.5年）后到期，一经发行即可行使，初始行权价为每股7.3575美元，并在第一个重置日和第二个重置日（如认股权证中所定义）进行调整，且受其中的最低价格限制。

The warrants may also be exercised on a zero cash exercise option pursuant to which the holder may exchange each warrant for 2.0 common shares..

认股权证也可能通过零现金行使期权的方式行使，持有者可将每份认股权证兑换为2.0股普通股。

Gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be $9.1 million. The offering is expected to close on June 6, 2025, subject to the satisfaction of customary closing conditions.

公司在扣除配售代理费用和其他发行费用之前的总收益预计为910万美元。此次发行预计将于2025年6月6日完成，但需满足惯例的交割条件。

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

Maxim Group LLC 担任本次发行的唯一配售代理。

A registration statement on Form S-1 (File No. 333-287572) was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on June 4, 2025. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at

一份S-1表格的注册声明（文件编号333-287572）已提交给美国证券交易委员会（“SEC”），并于2025年6月4日被SEC宣布生效。与此次发行相关的最终招股说明书将提交给SEC，并将在SEC的网站上提供，网址为

http://www.sec.gov

http://www.sec.gov

. The offering is being made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering, when available, may also be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, Attention: Syndicate Department, by telephone at (212) 895-3745 or by email at .

本次发行仅通过有效注册声明中包含的招股说明书进行。与本次发行相关的招股说明书的电子副本（在可用时）也可从 Maxim Group LLC 获取，地址：纽约州纽约市公园大道 300 号 16 楼，邮编 10022，联系人：辛迪加部门，电话：(212) 895-3745，或通过电子邮件联系。

syndicate@maximgrp.com

辛迪加@麦克斯集团。_com

.

。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或征求购买本文所述任何证券的要约，也不得在任何州或其他司法管辖区出售这些证券，因为在该等州或司法管辖区进行此类要约、征求或销售将违反其证券法下的注册或资格要求之前。

Forward Looking Statements

前瞻性声明

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties.

本新闻稿中的某些陈述并非基于历史事实，而是构成美国1995年私人证券诉讼改革法案和加拿大证券法所指的前瞻性陈述或前瞻性信息。本新闻稿中除历史事实陈述之外的所有陈述均为涉及风险和不确定性的前瞻性陈述。

Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding the completion of the public offering. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements.

前瞻性陈述通常通过诸如“相信”、“预期”、“继续”、“将”、“目标”、“旨在”等类似表述加以识别。此类前瞻性陈述包括但不限于有关完成公开发行的陈述。无法保证此类陈述的准确性，实际结果和未来事件可能与此类陈述中明示或暗示的内容存在重大差异。

Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, availability of funds, the Company’s ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company’s ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company’s ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” sect.

可能导致实际结果与公司预期存在重大差异的重要因素包括：与公司实现其业务目标的资本需求相关的不确定性、资金的可用性、公司寻找额外融资来源的能力、制造、劳动力短缺和供应链风险（包括与制造延迟相关的风险）、公司获得国家医疗保险覆盖和取得报销代码的能力、公司继续建立内部商业基础设施的能力、获取州分销许可证、市场对PoNS设备的认知、未来的临床试验和临床开发过程、产品开发过程以及FDA监管提交审查和批准流程、其他开发活动、持续的政府监管，以及“风险因素”部分不时详细说明的其他风险。

Investor Relations Contact:

投资者关系联系人：

Philip Trip Taylor

菲利普·特里普·泰勒

Gilmartin Group

吉尔马丁集团

investorrelations@heliusmedical.com

投资者关系@heliusmedical.com